胃と腸43巻2号

2008年02月発行

今月の主題 消化管GIST―診断・治療の新展開 主題

消化管GISTの診断と悪性度の評価―分子病理学的因子からみて

著者： 三橋智子¹ 長谷川匡¹

所属機関： ¹札幌医科大学医学部病理診断学

ページ範囲：P.157 - P.162

要旨　gastrointestinal stromal tumor（GIST）の大部分は，c-kitもしくはplatelet-derived growth factor receptor（PDGFR）αの機能獲得型変異によって発生することが解明されて以来，その診断・治療・予後に関する概念・戦略も大きく変化した．そのためGISTの悪性度評価も，形態組織学的方法から進んで，種々の分子病理学的方法を用いた検討に期待が寄せられるようになってきた．本稿では，分子病理学的因子からみたGISTの悪性度評価を検討した最近の知見から，細胞増殖関連抗原，細胞周期蛋白，c-kitとPDGFRα遺伝子異常，およびそのほかの遺伝子異常について概説する．

参考文献

1) Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors：A consensus approach. Hum Pathol 33：459-465, 2002

2) Fujimoto Y, Nakanishi Y, Yoshimura K, et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors：analysis of results in 140 surgically resected patients. Gastric Cancer 6：39-48, 2003

3) Nakamura N, Yamamoto H, Yao T, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36：828-837, 2005

4) Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor：consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 33：669-676, 2002

5) Yamaguchi U, Hasegawa T, Sakurai S, et al. Interobserver variability in histologic recognition, interpretation of KIT immunostaining and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. Appl Immunohistochem Mol Morphol 14：46-51, 2006

6) Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21：1688-1697, 2003

7) Schneider-Stock R, Boltze C, Lasota J, et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors：a tissue microarray study. Clin Cancer Res 11：638-645, 2005

8) Sakurai S, Fukayama M, Kaizaki Y, et al. Telomerase activity in gastrointestinal stromal tumors. Cancer 83：2060-2066, 1998

9) Günther T, Schneider-Stock R, Häckel C, et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 6：1811-1818, 2000

10) El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors：tumor progression and prognostic significance. Cancer Res 60：3899-3903, 2000

11) Gunawan B, Bergmann F, Höer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 33：316-321, 2002

12) Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16：1257-1264, 2003

13) Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 34：1306-1312, 2003

14) Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach：a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29：52-68, 2005

15) Miettinen M, Hakhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum：a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30：477-489, 2006

16) Lasota J, Vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumor. Lab Invest 87：1029-1041, 2007

17) Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38：679-687, 2007

18) Sakurai S, Hasegawa T, Sakuma Y, et al. Myxoid epithelioid gastrointestinal stromal tumor(GIST)with mast cell infiltrations：a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 35：1223-1230, 2004

19) Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10：3282-3290, 2004

20) Kang HJ, Nam SW, Kim H, et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24：1066-1074, 2005

21) House MG, Guo M, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 7：1004-1014, 2003

22) Koon N, Schneider-Stock R, Sarlomo-Rikala M, Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53：235-240, 2004

23) Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127：294-299, 2004

24) Chen LL, Sabripour M, Andtbacka RH, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7：293-299, 2005

25) Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11：4182-4190, 2005

26) Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128：270-279, 2005

27) Fukasawa T, Chong JM, Sakurai S, et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 91：1241-1249, 2000

28) Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 22：3813-3825, 2004

29) Lasota J, Wozniak A, Kopczynski J, et al. Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors(GISTs)：a study on 50 cases. Lab Invest 85：237-247, 2005

30) Allander SV, Nupponen NN, Ringner M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61：8624-8628, 2001

31) Price ND, Trent J, El-Naggar AK, et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci USA 104：3414-3419, 2007

32) Thompson MA, Ohnuma K, Abe M, et al. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 7：253-273, 2007